Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML [Yahoo! Finance]
Moleculin Biotech, Inc. (MBRX)
Last moleculin biotech, inc. earnings: 8/16 05:35 pm
Check Earnings Report
US:NASDAQ Investor Relations:
moleculin.com/investors
Company Research
Source: Yahoo! Finance
company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the completion of its End of Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for its Phase 1B /2 clinical trial evaluating Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as AnnAraC) for the treatment of subjects with AML as both first line therapy and for subjects who are refractory to or relapsed after induction therapy (MB-106). The Company expects to report outcomes from the EOP2 meeting upon receipt of official minutes from FDA which is expected by the end of Q3 2024. "The Moleculin team, along with our regulatory advisors and key opinion leaders, discussed with FDA the MB-106 safety and efficacy clinical findings and proposed next steps for our AML clinical development program," commented Walter Klemp , Chairman and Chief Executive Officer of Moleculin. "We are g
Show less
Read more
Impact Snapshot
Event Time:
MBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBRX alerts
High impacting Moleculin Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
MBRX
News
- Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference [Yahoo! Finance]Yahoo! Finance
- Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment ConferencePR Newswire
- Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment WebinarPR Newswire
- Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
MBRX
Sec Filings
- 9/3/24 - Form PRE
- 8/19/24 - Form 8-K
- 8/19/24 - Form 424B3
- MBRX's page on the SEC website